Member Info for pickedpeck

Did anyone miss the most significant signal dropped by this company all year?

Some basic linguistic forensics on Dr. Eric Leire’s recent Proactive interview means the core thesis here has just been massively de-risked.

Listen very carefully to how Eric framed the data progression from the lab to the SLAB canine trial. He didn't use future-looking, conditional, or defensive biotech hedging. He didn’t say "we hope to see" or "we are looking to evaluate efficacy."

He stated, as a plain, accomplished, matter-of-fact milestone:

"We demonstrated that we have efficacy in mice. Now, we demonstrated that we have efficacy in dogs."

Read that again. "We demonstrated." Past tense. An accomplished factual baseline.

So why isn't this an RNS yet?

Because under strict UK MAR compliance frameworks, a board cannot put a trial conclusion into a legally binding regulatory release until the CRO has finished unblinding, auditing, and binding every single statistical page. That physical cleanup takes months, which is why the comprehensive, academic data pack is slated for the Toronto stage in October.

But a CEO’s natural confidence cannot be completely muzzled in a live video interview. Eric Leire knows exactly what the unblinded trends look like. He knows what the data room looks like. His natural slip into the past tense confirms that the data sitting in Genflow's vault right now is a verified success.

Another signal is the rate of change in corporate activity happening concurrently:

The Human Translation: Eric explicitly stated that the dog trial results on muscle mass preservation and frailty reduction are actively being used to bridge straight into their human Sarcopenia program. The dog platform isn't a standalone side-hustle; it has successfully validated the entire SIRT6 human pipeline.

Gad Berdugo’s Boardroom Hunt: While retail complains about an autumn delay, the company quietly dropped an RNS confirming Chairman Gad Berdugo is at the BIO International Convention in San Diego right now (June 22–25). He isn't just handing out leaflets, he is sitting on a premier panel discussing the next 3–5 years of RNA and clinical validation.

So we have the CEO openly stating on camera that canine efficacy has been demonstrated, and you have a Wall Street M&A Chairman currently working the room at one of the largest biotechnology deal-making conventions on earth in California.

The Tier-1 companies currently under CDA in the data room are seeing the exact same efficacy data Leire just whispered to the market. They now have until October before that comprehensive dataset is laid bare to every global competitor in Toronto.

Of course the pharma companies with access to the data room are incentivised to not wait. Proven efficacy is proven value, scientifically accepted and ready to wrap into a deal package. A deal could happen literally any time from this afternoon onwards.

It seems some are reading this morning's RNS as a simple delay. However, if you look at the rate of change in messaging, a completely different story emerges.

​In corporate finance, a sudden, dramatic shift in a company's communication habits is one of the most reliable signals of major, live background activity.

​Historically, Eric Leire and the Genflow team have been incredibly forthcoming and highly promotional. Up until early April, we had a regular cadence of video interviews, interim updates, and active retail PR.

​Now look at the current rate of change:

​The 70-Day Video Gap: It has been exactly 10 weeks since Eric Leire last appeared on screen (April 8).

​The ACVIM Poster Silence: Last week, the company presented an abstract explicitly titled "SIRT6 Gene Therapy Improves Clinical Endpoints in Aged Dogs." Academic compliance strictly forbids using an active, definitive verb like "Improves" unless the quantitative metrics are unassailable. Yet, there was absolutely no follow-up video, no promotional victory lap, and no retail spin.

​If a micro-cap's trial data was failing, or if the data room negotiations had completely collapsed, management would be doing the exact opposite. They would be flooding the market with promotional videos and retail hype to artificially prop up the share price. Instead, they have turned the cameras completely off.

​This absolute silence following a successful scientific milestone is the classic footprint of strict regulatory compliance.

​With the SLAB trial physically concluding this month, the raw data is being unblinded, audited, and compiled. At the exact same time, multiple Tier-1 animal health giants are roaming the data room under CDAs.

​Under UK MAR frameworks, a CEO cannot jump on a video call and riff about ongoing trials or active commercial discussions. A single casual remark or an overly optimistic smile can violate safe harbor laws and compromise a multi-million-pound transaction. The board has locked down the communications channel because they are treating this data with the absolute security required for an institutional exit.

​

​The RNS announcing the Toronto presentation in October is not an extension of the quiet zone, it is the establishment of a hard boundary.

The Tier-1 suitors under CDA do not have to wait until October. They will be handed the raw, unblinded SLAB trial data packages the moment the labs finish processing them.

​By locking in a massive public showcase in October with global longevity leaders like Matt Kaeberlein and Vera Gorbunova, Berdugo has just put a ticking clock on the screen for the current bidders. He has told them: "The comprehensive dataset goes wide on October 1st. If you want an exclusive, proprietary deal, you have to get off the pot and sign a term sheet this summer before the open-season auction begins."

The transition from a loud, promotional R&D story to absolute corporate radio silence is a structural transition from marketing an asset tra

Marty,

The opposite. SIRT6 originated in humans, it's actually more of a surprise it works in dogs. In normal clinical development there are usually huge leaps from a petri dish to a mouse, a mouse to a large mammal, and a large mammal to a primate. The human step at the end is normally the last stage. However for SIRT6 the translation risk seems minimal given its human origins.

While I think the SLAB trial serves to massively accelerate the company's potential for sarcopenia there are significant issues remaining. The big challenge there is not whether it will work, but controlling the delivery to muscle tissue. A naked DNA approach would not be permitted in humans, and AAV8 has its own limitations so we come back to Acuitas and LNPs which have not yet been tested with SIRT6 for sarcopenia. That means the IND needs to use new technology not tried let alone proven via the SLAB trial.

The good news is that Acuitas has extra hepatic tech that focuses on muscle delivery, so hopefully it's not really breaking completely new ground, more combining working components.

You have to wonder whether Genflow is suddenly a more interesting target in more than just an animal health context.

Because SIRT6 the translation risk from animal to human is effectively nil. Success in a large mammal study clearly has multiple implications for human indications, the chief remaining risk in targeted delivery effectively mitigated by the Acuitas partnership.

Feel like I am holding my breath...!!

The answer I got back...

Thank you for your email and more importantly being a shareholder of Genflow.

I can assure you we are not withholding an RNS, the data being presented is an academic extension as you referenced in your email.

We have several groups in the data room currently and as such are constrained in making any further announcements.

As for our radio silence we have nothing of note at the moment to release to shareholders and the wider market, but rest assured as soon as we have any kind of tangible update we will issue a release.

Kind regards.

This is what I asked...

Hello,

I am a reasonably significant holder in Genflow Biosciences, holding approximately x.xx% of the company shares. My shares are held under ii/ABRDN so may not appear distinct on the register.

As a substantial shareholder with a background in clinical development, I see the ACVIM poster is going live today without an accompanying RNS.

Can you confirm if the data being presented in Seattle is strictly an academic expansion of the qualitative endpoints disclosed in the April 8th update, or is the company intentionally withholding a regulatory release to align with a formal peer-reviewed journal embargo?

Also given the company’s recent RNS regarding expanded CDAs with Tier-1 animal health giants, has the lack of a public data unblinding today been dictated by confidentiality constraints or non-disclosure parameters requested by parties currently in the data room?

Finally with the study's monitoring phase running through July and the Glaucoma abstract for AAO campaign (likely) kicking off in August, should backers look at the current radio silence as a deliberate strategy to bundle the final SLAB clinical data directly with a corporate asset transaction or trade sale announcement this summer?

The continued silence serves to repress enthusiasm for the company and has a knock on effects to the share price. I am simply seeking to understand the rationale for the silence. I look forward to your response.

Morning porter, you've been quiet, are you away camping?

Silence is frustrating but doesn't have a colour.

'Spidey sense' was right so far unless we get an RNS later in the day.

Through a clinical and regulatory lens, the absence of a 7:00 AM RNS points to three highly probable scenarios:

1. The "No New Inside Information" Safe Harbor: On April 8, Genflow issued an RNS confirming "sustained safety and efficacy" at the advanced stages of the SLAB trial. If the poster pinning up today in Seattle is simply the visual, academic layout of those identical conclusions without a fresh, fundamentally market-altering statistical unblinding, management’s legal counsel likely concluded it does not meet the strict statutory definition of new, price-sensitive inside information required to force a MAR disclosure.

2. The Buyer’s M&A Embargo: If Chairman Gad Berdugo is in late-stage, multi-party negotiations for the animal health Trade Sale, the Tier-1 corporate buyers hold the leverage. Big Pharma M&A committees loathe public market volatility during due diligence. They frequently demand total public silence on technical data points, requiring that the final unblinded metrics be kept strictly inside the confidential data room until the definitive asset-purchase agreement is signed.

3. The July Database Lock Alignment: In their April regulatory filings, Genflow noted the dog study technically continues monitoring through the end of July. If the full molecular database lock and audited methylation clock matrices aren't fully completed until then, today's poster is a highly encouraging clinical progress report for vets, but not the final, unblinded statistical package that triggers a corporate regulatory event.

Will be dropping a note to investor relations shortly to clarify, I'll post the note and response later.

The poster session at ACVIM tomorrow may or may not trigger an RNS, it all depends on the content of the poster and whether the company, and FCA, believe the content is significant enough to necessitate a release. There are arguments for an against.

Obviously the company is sat on data we have not seen yet, and that is almost certainly forming the basis of trade sale negotiations. They have to have enough evidence on the poster to back up the word 'Improves' for the end points. That's an argument for RNS.

However my 'spidy sense' says they may not blow the lid off the science tomorrow. Genflow has explicitly stated that their target for the complete dataset (including CRP assays and ALKP isoform fractionation) is a peer-reviewed scientific journal. High-impact medical and veterinary journals enforce draconian pre-publication embargo rules. If Genflow issues a detailed RNS tomorrow broadcasting the raw statistical tables and molecular breakthroughs they risk disqualifying themselves from publication in top-tier journals. They will want to show enough data in Seattle to captivate Big Pharma scouts, without leaking the granular data points that belong to the upcoming paper.

Also if Berdugo and Leire are in deep, late-stage asset-purchase negotiations with Tier-1 animal health buyers under those expanded confidentiality agreements, a public data explosion is the last thing they want.

​Publicly releasing the exact final numbers triggers retail volatility and speculation. A swinging share price can cause a corporate buyer’s legal and compliance committees to hesitate or pause negotiations to reassess terms.

​Big Pharma buyers prefer total confidentiality until the deal is done. Berdugo knows that the unblinded molecular data belongs in the private data room for the suitors who have signed CDAs, not on a public RNS for retail traders. The goal is likely to announce the Trade Sale agreement and the final data simultaneously later this summer, executing a clean corporate exit.

I'm about 50:50 whether there will be an RNS tomorrow, but will absolutely be checking at 7am.

Marty, I think your sums may be off. £100m mkt cap would be a share price about 17p.

100p would need a mkt cap of about £600m.

Its not impossible that post nasdaq listing that genf could reach that kind of valuation.

Marty - Experience of early stage clinical M&A, estimate of market size, comparative deals.

Stock zombie...

They are setting up a sequence of dominos. First the big data reveal, then the trade sale for animal health, then the glaucoma abstract publication in August, AAO in October with LNP delivered SIRT6 preserving RGCs, early 2027 opthalmology partnership, IND package for MASH early 2027 with a plan for FIH 2028, Sarcopenia development program and IND in 2027.

Each of these represents a value escalation poin, and market price depends on the market they are in. It seems inevitable that they will flip to NASDAQ at some point, the trade sale may deliver enough cash to do that on its own, but the glaucoma follow up definitely will.

I've been thinking about the different wording for the animal health program and the implications.

The fact the company used the phrase Trade Sale rather than acquisition implies there is a different basis of negotiation, and placing the timetable as Q2 as recently as mid May also implies the deal is imminent.

So what would a trade sale look like?

A lock stock and barrel deal where the buyer would be the one to integrate all future animal health development into their own programs. They wouldn't have a tricky ongoing research relationship with a UK mixcrocap, but would have all rights and technology associated with the program so far.

Valuation of the trade sale is entirely a function of the bidders, not the current mkt cap. Genflow has sufficient cash to continue it's programs without closing the sale so is not desperate. However we simply don't know if there is a bidding war or not.

Three point estimate of the value may be something like

Low - $15m up front, milestone payments ~$30m, 7% perpetual royalty

High - $50m up front, milestone payments ~$100m, 15% royalty

Expected (best guess) - $25m up front, $50m milestone payments, 10% royalty.

Worst case is no deal or requirement for further validation, we can't completely rule this out but it does seem very unlikely.

It's a good question, under MAR they will have to release prior to or simultaneously with the results. The poster session opens 9am Pacific time, so 5pm UK time on the 11th.

We should see an RNS, most likely at 7am on the 11th but has to be before the poster session opens.

Let me say that again and separately. I think slide 11 of the May corporate presentation is a classic corporate Easter egg, deliberately poorly labelled but showing the actual methylation clock data reversal from the SLAB trial.

The title of the slide includes the word 'Use' rather than 'Try' or 'trial'. Implicitly it shows methylation clock reversal, by a significant and measurable amount.

Sorry, that downplays it a bit. Even a poster in a top level event declaring age reversal will cause a tsunami of interest, but that tsunami is unlikely to be on the day but build over the next 2-4 weeks as the news spreads via the longevity press and commentators. If they really have as strongly hinted reversed the methylation clock data then that news is an earthquake in longevity.

It's not an on stage presentation, they are showing the results as a poster. It's a box ticking exercise in a scientific validation event. It's likely a prerequisite from prospective partners to show their data in a peer reviewed environment, but there is no need to do a sales pitch.

I'd like to think they would also RNS the results on the same day but they may not, even access to the details on the poster may be somewhat restricted. The day may come and go as a bit of a damp squib, but I'd hope Eric would at least do a video follow up with us private investors in mind.

I've been away, so maybe I have missed posts about this, apologies if so. But there definitely is not enough fuss about the updated corporate overview presentation the company posted on its website in May.

Go have a look if you haven't already. There are some significant updates in it.

As I said in the other post, the clinical endpoints for the SLAB trial are listed, scheduled for a reveal this week. That's big news in itself. I'm not entirely sure that slide 11 of the presentation that shows reversal of the epigenetic age in aged cells is not directly linked to the SLAB trial. It's poorly labelled, but seems to be the rationale for use of SIRT6 in aged dogs.

There are also significant updates on the glaucoma program, potentially with huge impact:

1. They are using LNPs to target retina cells.

2. There is a rodent POC with IRIS pharma in Q2/3 (now!!)

3. Go / no go for IND development work

4. Glaucoma partnership or ACQUISITION in 2027

5. Both MASH and Glaucoma under 24 months to first in human trials.

6. MASH program also targeted for ACQUISITION or partnership..

7. Q2 targeted for licensing out or TRADE SALE of the animal health program.

The presentation clarifies that the company intends to maximise value by selling the parts in sequence rather than the whole.

Anyway, looks like the right week to arrive back 😁

So combining the new corporate overview presentation information and the recent linkedin post tells us that this week should be fun!

This week (June 11–13, 2026), Genflow Biosciences touches down at the prestigious ACVIM Forum (American College of Veterinary Internal Medicine) in Seattle.

​For anyone who has been tracking the regulatory trail and corporate teasers, the title of Genflow’s presentation abstract tells you everything you need to know:

​"SIRT6 Gene Therapy IMPROVES Clinical Endpoints in Aged Dogs"

​Note the definitive use of the word "IMPROVES". This isn't a speculative look at what might happen; this is peer-reviewed, unblinded, living-organism data from the highly anticipated SLAB (Sarcopenia and Longevity in Aged Beagles) clinical trial.

​The 4 Key Clinical Endpoints

​Genflow has systematically targeted four foundational pillars of longevity medicine. Based on recent corporate updates and their data tracking, here is what is being unveiled and validated in Seattle:

​1. Epigenetic Age (The Methylation Clock): This is the holy grail of longevity science. While many biotechs boast about cellular rejuvenation in test tubes, Genflow is bringing hard data on the actual reversal of biological age in a complex, large-mammal model using advanced methylation clock analysis.

​2. Sarcopenia (Muscle Mass & Histology): Muscle wastage is a definitive marker of frailty in both aging dogs and humans. Following Genflow's international patent expansion into frailty and muscular diseases, the Seattle data provides quantitative validation via muscle biopsy histology, proving the preservation of tissue structure and functional strength.

​3. Lifespan & Healthspan Biomarkers: Blood analyses from the trial are diving deep. Look out for quantitative shifts involving CRP assays (chronic inflammation markers) and ALKP isoform fractionation. If GF-1002 has successfully quieted age-associated systemic inflammation, the biological data will prove a systemic "reset."

​4. Safety & Tolerability Profile: Gene therapies live and die by safety. At the 3-month interim, Genflow reported a flawless, zero-adverse-event profile. Re-confirming this total durability at the final milestone is the ultimate green light for global regulators and prospective commercial partners alike.

As Offgrid pointee out there is a Mind-Boggling Valuation Disconnect (UK vs. US)

​To put Genflow’s current ~£12.04 million market cap into perspective, look across the Atlantic. Just days ago, Silicon Valley-backed longevity competitor NewLimit secured a massive Series C round, valuing them at a whopping $3.1 Billion. They are a long way behind Genflow's development.

Maybe Genflow currently remains under the radar, but this week they are announcing how their defined endpoints were improved by the SLAB trial, potentially by using naked DNA making the treatment a commodity priced repeatable product.

If you haven't yet read the May 2026 updated corporate presentation go a

...contd

4. The Endgame: The Nasdaq Carve-Out Precedent

Let's look at why Gad Berdugo (former CBO of NASDAQ-listed CRISPR pioneer Editas Medicine) is actually here. He wasn't brought in to manage lab workflows; he's here for his Wall Street rolodex.

A simple asset sale or licensing deal into the illiquid London market often gets hit with a severe "conglomerate discount." The ideal structure—and maybe what Berdugo is quietly architecting in the background—is a Canine Joint Venture Carve-Out leading to an independent Nasdaq IPO.

The Setup: The Tier-1 pharma partner acts as the anchor co-founder of the new U.S. entity.

The Reward: Existing LSE shareholders are handed direct, tradable shares in the new Nasdaq vehicle via an in-specie distribution.

The Multiplier: The Nasdaq entity funds its own future clinical trials through deep U.S. longevity capital, establishing a massive valuation precedent (e.g., $100M+ floor) that automatically forces London to re-rate the remaining human assets left in the parent PLC.

The Bottom Line

The information vacuum that caused the recent message board jitters was necessary for the company to set up it's dominos (not pizza delivery!). The major holders have been muzzled because the regulatory MAR wall is incredibly tight when you are sequencing a multi-stage corporate exit.

The technical overhang that allowed weak hands to be matched out at 2p is nearing its mechanical end. The board has drawn their line in the sand, the marketing engine is active, and the corporate clock is ticking down to the June data gates. Hold tight.

PS - I'm not saying how many shares I have, I generally don't. I have got more than HSBC or HBOS, but not a notifiable quantity. The company probably doesn't see me as a major holder as mine are wrapped under an ii / ABRDN banner. I've definitely put a fair bit of money where my mouth is.

With that, back to radio silence, I should be back online before the poster presentation.

eh up.

just thought i would check in, i'm in tarbert harbour, daughter got married on tuesday, i'll be sailing again tomorrow.

the genflow linkedin update is important, the board has handed us a public countdown clock. don't mistake this for a simple marketing calendar, it's a tactical dual-purpose play aimed at two entirely different audiences.

here's my take on the corporate finance game playing out behind the scenes:

1. lighting a fuse under the cda holders

right now, we know multiple tier-1 animal health companies have data room access under confidentiality agreements (cdas). big pharma m&a teams are notorious for dragging out due diligence—constantly asking for "one more week" of analysis to minimize their own risk.

by explicitly laying out the june 2026 deadlines genflow has effectively lit a fuse in that data room. they are telling the current suitors: "you have until june to sign a term sheet. once the european patent grants and the full slab data pack drops in boston, exclusivity is dead and it becomes an all-comers open season auction." it is a high-stakes "**** or bust" move designed to force a binding offer imminently.

2. a calculated slow burn, not an instant pop

we need to temper expectations regarding the immediate market response to the data. scientific data rooms take time to digest.

however there is a linguistic tell. look at the acvim poster title: "sirt6 gene therapy improves clinical endpoints in aged dogs." academic compliance strictly forbids active verbs like "improves" unless the quantitative molecular metrics are undeniable.

the early-june (2 weeks away!) acvim poster is a low-expense, high-impact box-ticking exercise to satisfy pharma's internal scientific committees. the real closing tool is the late-june full slab trial publication (n=24 dataset with complex alkp fractionation and crp assays), with a goal of journal publication.

there will be a market lag to the announcements, generalist retail won't understand this data in 5 minutes. expect a multi-week analytical slow-burn where specialized biotech analysts model the net asset value (nav), leading to steady institutional accumulation rather than a chaotic 7:00 am screen explosion.

3. separation of church & state: preventing "valuation overwrite"

it is vital that the canine platform and the human gf-1006 glaucoma program remain completely independent. if they drop on top of one another, the lse's limited bandwidth will suffer from structural blindness, the market will focus entirely on the dog cash upfront and value the human platform at zero.

the corporate deck shows the human ophthalmology poc is due q2, with a definitive 18-month path to human trials using the newly secured acuitas lnp tech. by anchoring the major human glaucoma disclosures to the aug aao publication window, the board is ensuring june belongs entirely to the dog cleanup, leaving the late summer wide open for the human longevity asset to trigger its own distinct platform premium.